Next-generation sequencing (NGS) has given new perspective in oncology. With the ongoing development of targeted therapies, NGS is evolving molecular diagnostics by providing comprehensive interrogation of clinically actionable genomic aberrations in tumors. Having this assay as the primary testing method produces clinically beneficial results. See related article by Drilon et al., p. 3631.
No takes yet. Share an insight, caveat, or question.
McCutcheon et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: